文献速递糖尿病肥胖与代谢综合征

前神经降压素/神经介素N与代谢综合征及糖尿病发病风险:REGARDS队列研究

Pro-Neurotensin/Neuromedin N and Risk of Incident Metabolic Syndrome and Diabetes Mellitus in the REGARDS Cohort.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

研究纳入REGARDS队列3772名完成基线和随访检查的参与者,检测血浆前神经降压素/神经介素N(pro-NT/NMN)水平,分析其与新发代谢综合征(MetS)和糖尿病(DM)的关联。结果显示pro-NT/NMN每升高1个标准差,新发MetS的OR为1.22(95%CI 1.11-1.35),但与新发DM无显著关联(OR 1.06,95%CI 0.94-1.19)。

要点

  • pro-NT/NMN与代谢综合征发病风险正相关,校正人口学因素后OR为1.22。
  • 该关联在进一步校正HOMA-IR后减弱,提示胰岛素抵抗可能介导此关联。
  • pro-NT/NMN与新发糖尿病无显著关联。

核心结论

  • 血浆pro-NT/NMN水平升高与代谢综合征及其组分(血糖异常和低HDL)发病风险增加相关,但与非糖尿病新发糖尿病无关。
  • pro-NT/NMN与代谢综合征的关联可能由胰岛素抵抗解释。

研究设计与样本

  • 研究为REGARDS队列分析,纳入3772名完成基线(2003-2007)和随访(2013-2016)检查且具有pro-NT/NMN免疫测定数据的参与者。
  • 采用加权logistic回归模型分别分析新发糖尿病、新发代谢综合征及其各组分。

主要发现

  • 血浆pro-NT/NMN中位数(IQR)为160 pmol/L(118-218 pmol/L)。
  • 在基线无代谢综合征的2770名参与者中,564人发生代谢综合征;在基线无糖尿病的3030名参与者中,407人发生糖尿病。
  • 校正人口学因素后,log-pro-NT/NMN每升高1个标准差,新发代谢综合征的OR为1.22(95%CI 1.11-1.35),新发低HDL的OR为1.16(95%CI 1.00-1.35),新发血糖异常的OR为1.25(95%CI 1.11-1.40)。
  • 进一步校正HOMA-IR后,pro-NT/NMN与代谢综合征的关联减弱(OR 1.14,95%CI 1.00-1.30)。
  • pro-NT/NMN与新发糖尿病无显著关联(OR 1.06,95%CI 0.94-1.19)。

关键数值与推荐

  • 新发代谢综合征定义为基线时符合少于3项协调标准、随访时符合3项或以上协调标准。
  • 新发糖尿病定义为基线无糖尿病者随访时使用降糖药物/胰岛素、空腹血糖≥126 mg/dL或随机血糖≥200 mg/dL。

临床怎么用

  • pro-NT/NMN可能作为代谢综合征风险的生物标志物,但其临床价值需进一步验证。
  • 针对pro-NT/NMN升高的个体,应关注代谢综合征组分(尤其是血糖和HDL)的筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The peptide neurotensin is implicated in insulin resistance, diabetes mellitus (DM), and cardiovascular disease. OBJECTIVE: We studied the association of neurotensin's stable precursor, pro-neurotensin/neuromedin N (pro-NT/NMN) with incident metabolic syndrome (MetS) and DM. METHODS: We included 3772 participants from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study who completed the baseline exam (2003-2007), the follow-up exam (2013-2016), and had pro-NT/NMN measured by immunoassay. Weighted logistic regression models were fitted to incident DM, incident MetS, and each MetS component, separately, incorporating demographics, metabolic risk factors, homeostasis model of insulin resistance (HOMA-IR), and diet scores. Incident MetS was defined by 3 or more harmonized criteria at follow-up in those with fewer than 3 at baseline. Incident DM was defined by use of hypoglycemic drugs/insulin, fasting glucose 126 mg/dL or greater, or random glucose 200 mg/dL or greater in those without these at baseline. RESULTS: Median (IQR) plasma pro-NT/NMN was 160 pmol/L (118-218 pmol/L). A total of 564 (of 2770 without baseline MetS) participants developed MetS, and 407 (of 3030 without baseline DM) developed DM. Per SD higher log-pro-NT/NMN, the demographic-adjusted odds ratio (OR) and 95% CI of incident MetS was 1.22 (1.11-1.35), 1.16 (1.00-1.35) for incident low high-density lipoprotein (HDL), and 1.25 (1.11-1.40) for incident dysglycemia. The association of pro-NT/NMN with MetS was attenuated in the model adding HOMA-IR (OR per SD log-pro-NT/NMN 1.14; 95% CI, 1.00-1.30). There was no association with incident DM (OR per SD log-pro-NT/NMN 1.06; 95% CI, 0.94-1.19). CONCLUSION: Pro-NT/NMN was associated with MetS and 2 components, dysglycemia and low HDL, likely explained by insulin resistance.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nicoli CD, Carson AP, Plante TB, et al. Pro-Neurotensin/Neuromedin N and Risk of Incident Metabolic Syndrome and Diabetes Mellitus in the REGARDS Cohort. J Clin Endocrinol Metab. 2021. PMID: 34013344. doi:10.1210/clinem/dgab355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。